1. Home
  2. LQDA vs NSP Comparison

LQDA vs NSP Comparison

Compare LQDA & NSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • NSP
  • Stock Information
  • Founded
  • LQDA 2004
  • NSP 1986
  • Country
  • LQDA United States
  • NSP United States
  • Employees
  • LQDA N/A
  • NSP N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • NSP Professional Services
  • Sector
  • LQDA Health Care
  • NSP Consumer Discretionary
  • Exchange
  • LQDA Nasdaq
  • NSP Nasdaq
  • Market Cap
  • LQDA 1.9B
  • NSP 1.8B
  • IPO Year
  • LQDA 2018
  • NSP 1997
  • Fundamental
  • Price
  • LQDA $24.53
  • NSP $43.49
  • Analyst Decision
  • LQDA Strong Buy
  • NSP Hold
  • Analyst Count
  • LQDA 9
  • NSP 3
  • Target Price
  • LQDA $32.67
  • NSP $58.33
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • NSP 509.8K
  • Earning Date
  • LQDA 11-03-2025
  • NSP 11-03-2025
  • Dividend Yield
  • LQDA N/A
  • NSP 5.65%
  • EPS Growth
  • LQDA N/A
  • NSP N/A
  • EPS
  • LQDA N/A
  • NSP 1.05
  • Revenue
  • LQDA $19,322,000.00
  • NSP $6,695,000,000.00
  • Revenue This Year
  • LQDA $424.31
  • NSP $5.06
  • Revenue Next Year
  • LQDA $359.32
  • NSP $5.35
  • P/E Ratio
  • LQDA N/A
  • NSP $40.83
  • Revenue Growth
  • LQDA 30.20
  • NSP 2.40
  • 52 Week Low
  • LQDA $9.71
  • NSP $42.11
  • 52 Week High
  • LQDA $29.94
  • NSP $95.98
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 52.65
  • NSP 27.07
  • Support Level
  • LQDA $22.05
  • NSP $42.11
  • Resistance Level
  • LQDA $24.34
  • NSP $48.50
  • Average True Range (ATR)
  • LQDA 1.26
  • NSP 1.47
  • MACD
  • LQDA 0.10
  • NSP -0.27
  • Stochastic Oscillator
  • LQDA 60.51
  • NSP 9.47

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

Share on Social Networks: